Analyst Price Targets — RNAC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 12, 2026 10:16 am | — | H.C. Wainwright | $25.00 | $8.53 | TheFly | Cartesian Therapeutics price target lowered to $25 from $30 at H.C. Wainwright |
| March 9, 2026 2:57 pm | — | Cantor Fitzgerald | $16.00 | $9.02 | TheFly | Cartesian Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald |
| August 9, 2024 6:19 am | Mitchell Kapoor | H.C. Wainwright | $45.00 | $12.87 | TheFly | Cartesian Therapeutics price target lowered to $45 from $49 at H.C. Wainwright |
| July 3, 2024 7:55 am | John Newman | Canaccord Genuity | $43.00 | $15.77 | TheFly | Cartesian Therapeutics price target raised to $43 from $38 at Canaccord |
| May 24, 2024 5:35 am | Uy Ear | Mizuho Securities | $40.00 | $25.46 | StreetInsider | Mizuho Resumes Cartesian Therapeutics (RNAC) at Buy |
Latest News for RNAC
FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to eight new employees. On July 1, 2026, the Company issued to these employees options to purchase an aggregate of 238,700 shares of the Company's common stock with…
CZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.
FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee.
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) stock is up on Tuesday as the company is announcing a strategic licensing agreement with WestGene Biopharma.
WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans to advance multiple Cartesian-owned, internally developed next-generation anti-BCMA CAR constructs and a BCMA-directed TCE as part of expanding mRNA payload portfolio Clinical trial expected to initiate in 2H 2026 using…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RNAC.
U.S. House Trading
No House trades found for RNAC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.